Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 Aprile 2024 - 1:00PM
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical
stage biotechnology company developing innovative therapeutics to
treat rare fibro-inflammatory diseases with high unmet need, today
announced the publication of a new study that further confirms the
key role of its novel soluble protein target CCL24 in systemic
sclerosis (SSc). The study, “Serum CCL24 as a Biomarker of Fibrotic
and Vascular Disease Severity in Systemic Sclerosis,” was published
in the current edition of the journal Arthritis Care and
Research.
1
“This important new longitudinal study in a large cohort of
patients with SSc further confirms the extensive body of
preclinical evidence we have generated showing that CCL24 is a key
driver of the skin, lung and vascular complications in this
terrible condition that lacks disease-modifying therapies,” said
Adi Mor, PhD, a co-author of the publication and co-founder, CEO
and CSO of Chemomab. “These results also reinforce our belief,
based on multiple preclinical and patient sample studies, that our
novel CCL24-neutralizing antibody CM-101 has substantial potential
as a treatment for SSc. Our SSc program is Phase 2-ready with an
open US IND, with possible initiation of patient enrollment after
the topline readout from our Phase 2 trial in primary sclerosing
cholangitis that is expected in the next few months.”
The longitudinal study was conducted by prominent SSc
researchers at the University of Leeds in the UK and included more
than 200 patients. It explored the relationship between serum CCL24
levels and SSc severity and prognosis. One in four patients in a
real-life SSc population was found to have a high CCL24 serum
concentration, despite standard of care treatment with
immunosuppressive therapy. The analysis found that higher CCL24
levels were linked to critical clinical variables associated with
the most severe forms of SSc. They include severity of skin
fibrosis and calcinosis, presence of interstitial lung disease
(ILD), lung microvascular impairment, and a history of digital
ulcers and synovitis.
Crucially, high serum CCL24 was predictive of lung deterioration
and a higher baseline CCL24 level was associated with higher
10-year SSc-related mortality. The association of CCL24 with rapid
ILD progression and higher mortality was found to be independent of
disease duration and demographic and other factors, highlighting
its prognostic value over traditional clinical prognostic
indicators. The authors conclude that the findings support the
involvement of CCL24 in the pathophysiology of SSc and underscore
its potential as a promising therapeutic target for patients with
the disease.
Professor Francesco Del Galdo , lead author of the new
publication and Head of the Raynaud’s and Scleroderma Programme,
Leeds Institute of Rheumatic and Musculoskeletal Medicine,
University of Leeds, UK, commented, “This is a crucial addition to
the preclinical studies on the role of CCL24 in SSc, supporting the
involvement of this profibrotic chemokine in key clinical
manifestations of systemic sclerosis. The results provide further
evidence that a CCL24-neutralizing antibody such as CM-101 could
potentially be a valuable therapy for this devastating disease that
has limited treatment options. ”
1 - Serum CCL24 as a biomarker of fibrotic and vascular disease
severity in Systemic Sclerosis, Enrico De Lorenzis MD PhD, Adi Mor
PhD, Rebecca L. Ross PhD, Stefano Di Donato MD, Revital Aricha PhD,
Ilan Vaknin PhD, Francesco Del Galdo MD PhD, Arthritis Care &
Research, https://doi.org/10.1002/acr.25344
Forward Looking Statements This press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act. These forward-looking
statements include, among other things, statements regarding the
clinical development pathway for CM-101; the expectation that
Chemomab will report topline data from the PSC clinical trial by
mid-year 2024; the length, duration and impact of the war in Israel
on Chemomab’s business and operations; the future operations of
Chemomab and its ability to successfully initiate and complete
clinical trials and achieve regulatory milestones; the nature,
strategy and focus of Chemomab; the development and commercial
potential and potential benefits of any product candidates of
Chemomab; and that the product candidates have the potential to
address high unmet needs of patients with serious fibrosis-related
diseases and conditions. Any statements contained in this
communication that are not statements of historical fact may be
deemed to be forward-looking statements. These forward-looking
statements are based upon Chemomab's current expectations.
Forward-looking statements involve risks and uncertainties. Because
such statements deal with future events and are based on Chemomab's
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
Chemomab could differ materially from those described in or implied
by the statements in this presentation, including those found under
the caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based, except as required by law.
About Chemomab Therapeutics Ltd.Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
that neutralizes CCL24 activity. In clinical and preclinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported positive results from three clinical trials of CM-101
in patients, including a Phase 2a liver fibrosis trial in NASH
patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with topline data
expected midyear 2024. Chemomab’s CM-101 program for the treatment
of systemic sclerosis is Phase 2-ready with an open U.S. IND. For
more information about Chemomab, visit chemomab.com.
Contact:
Media and Investors:Barbara LindheimConsulting
Vice President, Investor & Public Relations, Strategic
CommunicationsPhone: +1
917-355-9234barbara.lindheim@chemomab.comIR@chemomab.com
Grafico Azioni Chemomab Therapeutics (NASDAQ:CMMB)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Chemomab Therapeutics (NASDAQ:CMMB)
Storico
Da Giu 2023 a Giu 2024